M Burnier

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi request reprint Novel angiotensin II inhibitors in cardiovascular medicine
    M Burnier
    Division of Hypertension and Vascular Medicine, Av P Decker, 1011 Lausanne, Switzerland
    Expert Opin Investig Drugs 10:1957-64. 2001
  2. ncbi request reprint Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions
    M Burnier
    Division of Hypertension and Vascular Medicine and Policlinique Médicale Universitaire, Lausanne, Switzerland
    J Hypertens 19:335-41. 2001
  3. ncbi request reprint Renal sodium handling in acute and chronic salt loading/depletion protocols: the confounding influence of acute water loading
    M Burnier
    Department of Medicine, CHUV, Lausanne, Switzerland
    J Hypertens 18:1657-64. 2000
  4. ncbi request reprint Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension
    M Burnier
    Centre Hospitalier Universitaire Vaudois, Department of Medicine, Division of Hypertension and Vascular Medicine, Lausanne, Switzerland
    Blood Press Monit 5:S31-4. 2000
  5. ncbi request reprint Angiotensin II receptor antagonists
    M Burnier
    Department of Medicine, Centre Hospitalier Universitaire, Lausanne, Switzerland
    Lancet 355:637-45. 2000
  6. ncbi request reprint Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects
    M Burnier
    Department of Medicine, CHUV, Lausanne, Switzerland
    Eur J Clin Pharmacol 55:633-7. 1999
  7. ncbi request reprint [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension]
    Michel Burnier
    Division d Hypertension et de Médecine Vasculaire, CHUV, Lausanne, Suisse
    Drugs 62:21-9. 2002
  8. ncbi request reprint Comparative antihypertensive effects of angiotensin II receptor antagonists
    M Burnier
    Division of Hypertension and Vascular Medicine, Lausanne, Switzerland
    J Am Soc Nephrol 10:S278-82. 1999
  9. ncbi request reprint Angiotensin II receptor antagonists in hypertension
    M Burnier
    Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland
    Kidney Int Suppl 68:S107-11. 1998
  10. ncbi request reprint Monitoring compliance in resistant hypertension: an important step in patient management
    Michel Burnier
    Policlinique Medicale Universitaire, Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Hypertens Suppl 21:S37-42. 2003

Collaborators

Detail Information

Publications147 found, 100 shown here

  1. ncbi request reprint Novel angiotensin II inhibitors in cardiovascular medicine
    M Burnier
    Division of Hypertension and Vascular Medicine, Av P Decker, 1011 Lausanne, Switzerland
    Expert Opin Investig Drugs 10:1957-64. 2001
    ..In addition, the future perspectives of drugs with dual mechanisms of action, such as NEP/ACE inhibitors, also named vasopeptidase inhibitors, are presented...
  2. ncbi request reprint Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions
    M Burnier
    Division of Hypertension and Vascular Medicine and Policlinique Médicale Universitaire, Lausanne, Switzerland
    J Hypertens 19:335-41. 2001
    ..The goal of this study was to evaluate the potential benefits of electronic monitoring of drug compliance in the management of patients with resistant hypertension...
  3. ncbi request reprint Renal sodium handling in acute and chronic salt loading/depletion protocols: the confounding influence of acute water loading
    M Burnier
    Department of Medicine, CHUV, Lausanne, Switzerland
    J Hypertens 18:1657-64. 2000
    ..The goal was to compare the changes in proximal and distal sodium handling induced by the two procedures using the lithium clearance technique...
  4. ncbi request reprint Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension
    M Burnier
    Centre Hospitalier Universitaire Vaudois, Department of Medicine, Division of Hypertension and Vascular Medicine, Lausanne, Switzerland
    Blood Press Monit 5:S31-4. 2000
    ..This article discusses different types of compliance, methods of measuring compliance, and the clinical consequences of noncompliance in hypertension...
  5. ncbi request reprint Angiotensin II receptor antagonists
    M Burnier
    Department of Medicine, Centre Hospitalier Universitaire, Lausanne, Switzerland
    Lancet 355:637-45. 2000
    ..Trials now underway will demonstrate whether angiotensin II receptor antagonists can prevent target-organ damage and reduce cardiovascular morbidity and mortality. If they do, these compounds might one day replace ACE inhibitors...
  6. ncbi request reprint Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects
    M Burnier
    Department of Medicine, CHUV, Lausanne, Switzerland
    Eur J Clin Pharmacol 55:633-7. 1999
    ....
  7. ncbi request reprint [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension]
    Michel Burnier
    Division d Hypertension et de Médecine Vasculaire, CHUV, Lausanne, Suisse
    Drugs 62:21-9. 2002
    ..We now need to know whether these agents are capable of reducing the cardiovascular morbidity and mortality associated with hypertension. To this purpose, several large clinical trials are ongoing and we are eager to read their results...
  8. ncbi request reprint Comparative antihypertensive effects of angiotensin II receptor antagonists
    M Burnier
    Division of Hypertension and Vascular Medicine, Lausanne, Switzerland
    J Am Soc Nephrol 10:S278-82. 1999
    ..Several large clinical trials of ARB are now under way to demonstrate their benefits in hypertension, heart failure, and type II diabetic nephropathy...
  9. ncbi request reprint Angiotensin II receptor antagonists in hypertension
    M Burnier
    Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland
    Kidney Int Suppl 68:S107-11. 1998
    ..Large clinical trials are now underway to demonstrate the long-term benefits of these agents in hypertension, heart failure and type II diabetic nephropathy...
  10. ncbi request reprint Monitoring compliance in resistant hypertension: an important step in patient management
    Michel Burnier
    Policlinique Medicale Universitaire, Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Hypertens Suppl 21:S37-42. 2003
    ....
  11. ncbi request reprint Sodium balance and hypertension: rare genetic disorders expose pathogenic mechanisms
    M Burnier
    Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland
    Exp Nephrol 6:496-501. 1998
    ..This review presents the pathogenic mechanisms revealed by these rare disorders and discusses the possible implication of these discoveries for the understanding of the pathophysiology of essential hypertension...
  12. pmc Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey
    Michel Burnier
    Service de Nephrologie, CHUV, Lausanne, Switzerland
    BMC Cardiovasc Disord 5:13. 2005
    ..The goal of this survey was to evaluate the tolerance and the blood pressure lowering effect of irbesartan as well as the factors affecting persistence in a large unselected population...
  13. ncbi request reprint Proximal sodium reabsorption: An independent determinant of blood pressure response to salt
    A Chiolero
    Division of Hypertension and Vascular Medicine, CHUV, , Lausanne, Switzerland
    Hypertension 36:631-7. 2000
    ..These results suggest that proximal sodium reabsorption is an independent determinant of the BP response to salt in hypertension...
  14. ncbi request reprint Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay
    M P Maillard
    Division of Hypertension and Vascular Medicine, University Hospital, Lausanne, Switzerland
    Am J Hypertens 12:1201-8. 1999
    ..This standardized in vitro-binding assay represents a simple, reproducible, and precise tool to characterize the pharmacodynamic profile of AngII receptor antagonists in humans...
  15. ncbi request reprint Compensatory up-regulation of angiotensin II subtype 1 receptors in alpha ENaC knockout heterozygous mice
    Q Wang
    Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland
    Kidney Int 59:2216-21. 2001
    ..The purpose of the present experiments was to examine how alpha ENaC knockout heterozygous (+/-) mice, which have only one allele of the gene encoding for the alpha subunit of ENaC, control their blood pressure (BP) and sodium balance...
  16. ncbi request reprint Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout
    G Würzner
    Division of Hypertension and Vascular Medicine, CHUV, 1011 Lausanne, Switzerland
    J Hypertens 19:1855-60. 2001
    ..i.d. has a greater impact on serum uric acid levels than losartan 50 mg once a day...
  17. ncbi request reprint Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6
    M P Maillard
    Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, Switzerland
    J Cardiovasc Pharmacol 35:383-9. 2000
    ..In conclusion, UR-7247 is a long-lasting, well-tolerated AT1 receptor in healthy subjects...
  18. ncbi request reprint Renal and neurohormonal responses to increasing levels of lower body negative pressure in men
    G Würzner
    Division of Hypertension and Vascular Medicine, Department of Medicine, CHUV, Lausanne, Switzerland
    Kidney Int 60:1469-76. 2001
    ....
  19. doi request reprint Inflammatory markers and blood pressure: sex differences and the effect of fat mass in the CoLaus Study
    M Pruijm
    Department of Nephrology, Lausanne University Hospital CHUV, Lausanne, Switzerland
    J Hum Hypertens 27:169-75. 2013
    ..The stronger associations in women suggest that sex differences might exist in the complex interplay between BP and inflammation...
  20. ncbi request reprint Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding
    M P Maillard
    Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, Lausanne, Switzerland
    J Pharmacol Exp Ther 295:649-54. 2000
    ..The antagonistic effect of enoltasosartan appears later. The delayed in vivo blockade effect observed for enoltasosartan appears to be due to a high and tight protein binding and a slow dissociation process from the carrier...
  21. doi request reprint Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects
    J Smolander
    Service de Nephrologie, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Pharmacol Ther 85:628-34. 2009
    ..It is suggested that avosentan dose-dependently induces sodium retention by the kidney, mainly through proximal tubular effects. The potential clinical benefits of avosentan should therefore be investigated at doses of <or= 5 mg...
  22. doi request reprint [Effects of nighttime and daytime interval definition on blood pressure and dipping in patients referred for ambulatory blood pressure measurement]
    M E Muller
    Service de néphrologie et d hypertension, CHU Vaudois, Rue du Bugnon 17, 1011 Lausanne, Suisse
    Ann Cardiol Angeiol (Paris) 61:193-7. 2012
    ..Ambulatory blood pressure monitoring (ABPM) has become indispensable for the diagnosis and control of hypertension. However, no consensus exists on how daytime and nighttime periods should be defined...
  23. doi request reprint Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals
    A Zanchi
    Service of Nephrology, Department of Medicine, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Diabetologia 53:1568-75. 2010
    ..This study examines the effects of pioglitazone on renal sodium handling in individuals prone to insulin resistance, i.e. those with diabetes and/or hypertension...
  24. doi request reprint Potassium restores vasorelaxation of resistance arterioles in non-hypertensive DOCA/salt fed mice
    C Wyss
    Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Microvasc Res 84:340-4. 2012
    ..Potassium-enriched diets exert renal and cardiovascular protective effects, but the underlying mechanisms are largely unknown...
  25. ncbi request reprint The return of increased blood pressure after discontinuation of antihypertensive treatment is associated with an impaired post-ischemic skin blood flow response
    D Sieg-Dobrescu
    , Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Hypertens 19:1387-92. 2001
    ..This impaired response may be due to the development of endothelial dysfunction, vascular remodeling, or both, and might contribute to the return of blood pressure to hypertensive values after withdrawal of antihypertensive therapy...
  26. doi request reprint Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans
    Lionel Coltamai
    Service of Nephrology and Hypertension Consultation, Department of Medicine, CHUV, Lausanne, Switzerland
    J Hypertens 28:520-6. 2010
    ....
  27. ncbi request reprint [Do endothelin receptors antagonists have a place in the treatment of arterial hypertension?]
    V Forni
    Service de Néphrologie et Hypertension, Departement de Medecine, CHUV, 1011 Lausanne
    Rev Med Suisse 7:1752-6. 2011
    ..In this article we will review the phases of the development ERAs, and their current and future place as therapeutic tool against arterial hypertension...
  28. ncbi request reprint In vitro effects of DuP 753, a nonpeptide angiotensin II receptor antagonist, on human platelets and rat vascular smooth muscle cells
    M Burnier
    Hypertension Division, University Hospital, Lausanne, Switzerland
    Am J Hypertens 4:438-43. 1991
    ..These results demonstrate that DuP 753 competes with angiotensin II binding to its receptor in both animal and human cells and selectively blocks the cellular response to angiotensin II...
  29. doi request reprint Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril
    M Burnier
    Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Int J Clin Pract 65:127-33. 2011
    ..The use of 'forgiving' drugs (i.e. drugs with duration of action longer than the 24-h dosing interval) may allow an adequate blood pressure (BP) reduction to be maintained despite missed doses...
  30. ncbi request reprint The future of angiotensin II inhibition in cardiovascular medicine
    Pascal Meier
    Department of Nephrology, University Hospital, Lausanne, Switzerland
    Curr Drug Targets Cardiovasc Haematol Disord 5:15-30. 2005
    ..Recent studies have shown that SPP 100 lowers blood pressure in hypertensive patients as effectively as an Ang II receptor antagonist...
  31. ncbi request reprint Telmisartan/hydrochlorothiazide: a new fixed dose combination
    Marc Maillard
    Service de Nephrologie, Rue du Bugnon 17, CHUV 1011 Lausanne, Switzerland
    Expert Rev Cardiovasc Ther 3:375-86. 2005
    ..The pharmacokinetics and -dynamics of the combination are similar to monotherapy, and the addition of hydrochlorothiazide to telmisartan does not modify the excellent tolerability profile of the drug...
  32. ncbi request reprint Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring
    Valérie Santschi
    Policlinique Medicale Universitaire, Lausanne, Switzerland
    Eur J Clin Pharmacol 63:1179-84. 2007
    ..The goal of this study was to evaluate clinically the acceptability of the IDAS II (Intelligent Drug Administration System), a new electronic device that enables drug adherence monitoring...
  33. ncbi request reprint Difficult blood pressure control: watch out for non-compliance!
    Kaisa Wuerzner
    Division of Hypertension and Vascular Medicine, Avenue P Decker, 1011 Lausanne, Switzerland
    Nephrol Dial Transplant 18:1969-73. 2003
  34. ncbi request reprint [New radiological techniques to investigate patients suffering from chronic kidney disease]
    M Pruijm
    Service de Nephrologie, CHUV, Lausanne
    Rev Med Suisse 7:505-9. 2011
    ....
  35. ncbi request reprint [Renal sympathetic denervation: perspective of a promising treatment for hypertension]
    M Cassat
    Service de néphrologie et d hypertension, CHUV, 1011 Lausanne
    Rev Med Suisse 7:1743-7. 2011
    ..However, long term morbidity and mortality of this technique are still not known...
  36. ncbi request reprint Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients
    M Pruijm
    Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Nephrol 72:199-205. 2009
    ..In this study we have evaluated the impact of measuring adherence to cinacalcet-HCl and phosphate binders in dialysis patients with uncontrolled secondary hyperparathyroidism...
  37. ncbi request reprint [Abnormalities of renal sodium transport and blood pressure sensitivity to salt]
    M Burnier
    Service de Néphrologie et Hypertension, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 17, 1011 Lausanne, Switzerland
    Nephrol Ther 3:S94-8. 2007
    ..There is now also extending experimental, clinical, genetic and epidemiological evidence suggesting that proximal tubular function is an important determinant of the blood pressure response to salt that would deserve a greater attention...
  38. ncbi request reprint [Plasmapheresis, a safe treatment when applied to the correct indication and with awareness of the complications]
    M T Pruijm
    Centre Hospitalier Universitaire Vaudois, Service de Néphrologie et Consultations d Hypertension, Departement de Medecine, Rue du Bugnon 17, 1011 Lausanne, Zwitserland
    Ned Tijdschr Geneeskd 152:2261-6. 2008
    ..Adverse effects of the treatment include disturbances of the acid-base equilibrium or the coagulation, and allergic reactions. Most of these complications, however, can nowadays be avoided...
  39. ncbi request reprint [Angiotensin II receptor blockers (ARBs) and cancer: a reassuring balance]
    M Cassat
    Division de physiopathologie clinique, CHUV, 1011 Lausanne
    Rev Med Suisse 7:1757-8, 1760. 2011
    ..Overall the bulk of evidence today indicates that ARBs are not associated with an increased cancer risk...
  40. doi request reprint Association between white-coat effect and blunted dipping of nocturnal blood pressure
    Murielle Bochud
    Institut Universitaire de Medecine Sociale et Preventive, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Am J Hypertens 22:1054-61. 2009
    ..In this study, we assessed whether the white-coat effect (difference between office and daytime blood pressure (BP)) is associated with nondipping (absence of BP decrease at night)...
  41. ncbi request reprint Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent
    Catherine Falconnet
    Division of Hypertension and Vascular Medicine, CHUV, Lausanne, University Institute for Social and Preventive Medicine, Lausanne, Switzerland
    J Hypertens 22:1213-20. 2004
    ..The efficacy of angiotensin-converting enzyme (ACE) inhibitors in decreasing blood pressure in African patients is controversial...
  42. ncbi request reprint Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men
    Frédéric Regamey
    Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland
    Hypertension 40:266-72. 2002
    ..Omapatrilat combines potent ACE inhibition with a sustained natriuresis, which explains its well-documented potent antihypertensive efficacy...
  43. ncbi request reprint The comparative pharmacology of angiotensin II receptor antagonists
    M Burnier
    Division of Hypertension and Vascular Medicine, University of Lausanne, Switzerland
    Blood Press Suppl 1:6-11. 2001
    ....
  44. ncbi request reprint [Obesity: what impact on renal function?]
    C Mathieu
    Service de Nephrologie et Consultation d Hypertension, CHUV, 1011 Lausanne
    Rev Med Suisse 2:576-8, 580-1. 2006
    ..The most important therapeutic approach is weight reduction. Angiotension converting enzyme (ACE) inhibition is effective in reducing proteinuria, but longer follow-up is required to determine the long term benfits of ACE inhibition...
  45. ncbi request reprint [Lercanidipine, a third generation calcium antagonist. Which advantages?]
    P Meier
    Service de Nephrologie et Consultation d Hypertension, CHUV, 1011 Lausanne
    Rev Med Suisse 2:2047-50, 2052-3. 2006
    ....
  46. ncbi request reprint [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?]
    C Mathieu
    Abteilung für Nephrologie, Centre Hospitalier Universitaire Vaudois, Lausanne
    Praxis (Bern 1994) 94:1851-8. 2005
    ..Regarding these data, COX-2 inhibitors should be prescribed with much caution to high risk patients, that is, patients with renal failure and/or cardiovascular diseases...
  47. ncbi request reprint A mouse model for Liddle's syndrome
    S Pradervand
    Institut de Pharmacologie et de Toxicologie de l Université, Lausanne, Switzerland
    J Am Soc Nephrol 10:2527-33. 1999
    ..This animal model reproduces to a large extent a human form of salt-sensitive hypertension and establishes a causal relationship between dietary salt, a gene expressed in kidney and hypertension...
  48. ncbi request reprint Efficacy of enzyme replacement therapy in Fabry disease
    F Barbey
    Division of Nephrology, Lausanne University Hospital, Switzerland
    Curr Med Chem Cardiovasc Hematol Agents 2:277-86. 2004
    ....
  49. ncbi request reprint [Retroperitoneal fibrosis, an unrecognized inflammatory disease. Clinical observations and review of the literature]
    P Meier
    Division de Néphrologie, Departement de Medecine, Hopital de Sion
    Nephrologie 24:173-80. 2003
    ..In most instances, RF does not lead to long-term morbidity or affect survival. The three cases of RF reported herein illustrate the varied mode of presentation and the response to the treatment...
  50. ncbi request reprint [Diagnosis of renal cysts]
    G Wuerzner
    Service de Nephrologie et Consultation d Hypertension, Lausanne
    Rev Med Suisse 1:534-8, 541-2. 2005
    ..The definitive diagnosis of many of the renal cystic diseases requires clinical, radiological, pathological, and genetic analysis. A precise diagnosis is essential for prognosis, treatment, and future genetic counselling...
  51. ncbi request reprint Physicians' estimates of the 10 year cardiovascular risk in hypertensive patients: an evaluation in primary care physicians in training
    Michele Senn
    Policlinique Medicale Universitaire, Lausanne, Switzerland
    Swiss Med Wkly 136:603-8. 2006
    ..To evaluate how young physicians in training perceive their patients' cardiovascular risk based on the medical charts and their clinical judgment...
  52. ncbi request reprint Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes
    Qing Wang
    Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Am Soc Nephrol 13:1509-16. 2002
    ..Finally, these data provide further evidence that mineralocorticoids promote cardiac hypertrophy even in the absence of BP changes. This hypertrophic process is mediated in part by the activation of angiotensin II AT(1) receptors...
  53. pmc Monitoring one-year compliance to antihypertension medication in the Seychelles
    Pascal Bovet
    Institut Universitaire de Medecine Sociale et Preventive, Lausanne, Switzerland
    Bull World Health Organ 80:33-9. 2002
    ..To examine the compliance to medication among newly diagnosed hypertensive patients screened from the general population of the Seychelles, a rapidly developing country...
  54. ncbi request reprint Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes
    Michel Burnier
    Service de Nephrologie, Department of Medicine, Lausanne Switzerland
    J Hypertens 24:11-25. 2006
    ....
  55. ncbi request reprint Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing
    Marc P Maillard
    Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, Switzerland
    Clin Pharmacol Ther 71:68-76. 2002
    ..In this study we investigated the importance of drug dosing in mediating these differences by comparing the AT(1)-receptor blockade induced by 3 doses of valsartan with that obtained with 3 other antagonists at given doses...
  56. ncbi request reprint Reactive rise in blood pressure upon cuff inflation: cuff inflation at the arm causes a greater rise in pressure than at the wrist in hypertensive patients
    Alexia Charmoy
    Division of Nephrology and Hypertension Consultation, University Hospital, Lausanne, Switzerland
    Blood Press Monit 12:275-80. 2007
    ..In this study, we compared the reactive rise in blood pressure induced by cuff inflation when the cuff was placed at the upper arm level and at the wrist...
  57. ncbi request reprint Effects of selective angiotensin II and beta1-receptor blockade on renal haemodynamics and sodium handling during orthostatic stress in healthy individuals
    Gregoire Wuerzner
    Service de Nephrologie et Consultation d Hypertension, CHUV, Lausanne, Switzerland
    J Hypertens Suppl 24:S89-93. 2006
    ..Both angiotensin II receptor blockers and beta-blockers have been shown to reduce morbidity and mortality in patients with congestive heart failure...
  58. ncbi request reprint [Monitoring drug adherence for hypertensive and dyslipidemic patients in networks of community-based pharmacists and physicians]
    Valérie Santschi
    Division de néphrologie et Consultation d hypertension, CHUV, Lausanne
    Rev Med Suisse 4:1928, 1930-2, 1934 passim. 2008
    ..The study also shows the value of collaboration between physicians and pharmacists in the field of patient adherence to improve ambulatory care of patients with cardiovascular risk factors...
  59. doi request reprint Effect of sodium loading/depletion on renal oxygenation in young normotensive and hypertensive men
    Menno Pruijm
    Service of Nephrology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 17, 1011 Lausanne, Switzerland
    Hypertension 55:1116-22. 2010
    ..These data demonstrate that dietary sodium intake influences renal tissue oxygenation, low sodium intake leading to an increased renal medullary oxygenation both in normotensive and young hypertensive subjects...
  60. ncbi request reprint Medication adherence and persistence as the cornerstone of effective antihypertensive therapy
    Michel Burnier
    Service de Nephrologie et Consultation d Hypertension, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    Am J Hypertens 19:1190-6. 2006
    ....
  61. ncbi request reprint Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults
    Nicolas Rodondi
    Cardiovascular Prevention Clinic, University Outpatient Clinic, Institute of Social and Preventive Medicine, Department of Community Medicine and Public Health, University of Lausanne, and Kantonsspital, St Gallen, Switzerland
    Nephrol Dial Transplant 22:1107-14. 2007
    ..Moreover, no study has compared cystatin C and microalbuminuria as risk factors for CVD outcomes in middle-aged adults, and it is not known whether cystatin C is related to an early stage of atherosclerosis...
  62. ncbi request reprint In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist
    Marc P Maillard
    Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, CHUV CH 1011 Lausanne, Switzerland
    J Pharmacol Exp Ther 302:1089-95. 2002
    ..Taken together, our in vitro data show that the insurmountable antagonism of telmisartan is due at least in part to its very slow dissociation from AT1 receptors...
  63. ncbi request reprint The safety of rofecoxib
    Michel Burnier
    Department of Nephrology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon, 1011 Lausanne, Switzerland
    Expert Opin Drug Saf 4:491-9. 2005
    ....
  64. ncbi request reprint Assessing the prevalence of hypertension in populations: are we doing it right?
    Pascal Bovet
    University Institute of Social and Preventive Medicine, Rue du Bugnon 17, 1005 Lausanne, Switzerland
    J Hypertens 21:509-17. 2003
    ....
  65. ncbi request reprint Discordant prevalence of hypertension using two different automated blood pressure measurement devices: a population-based study in Dar es Salaam (Tanzania)
    Arnaud Chiolero
    Institute of Social and Preventive Medicine, University of Lausanne, Switzerland
    Blood Press Monit 9:59-64. 2004
    ..We compared blood pressure readings obtained with an automated oscillometric arm-cuff device and with an automated oscillometric wrist-cuff device and then assessed the prevalence of defined blood pressure categories...
  66. ncbi request reprint Patients' sibling history was sensitive for hypertension and specific for diabetes
    Murielle Bochud
    University Institute for Social and Preventive Medicine, Rue du Bugnon 17, 1005 Lausanne, Switzerland
    J Clin Epidemiol 57:497-501. 2004
    ..We examined the analytic validity of reported family history of hypertension and diabetes among siblings in the Seychelles...
  67. ncbi request reprint AT1-receptor antagonism in hypertension: what has been learned with irbesartan?
    Bernard Waeber
    University Hospital, Division of Pathophysiology, Lausanne, Switzerland
    Expert Rev Cardiovasc Ther 1:23-33. 2003
    ..Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients...
  68. ncbi request reprint Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
    Arnaud Chiolero
    Division of Hypertension and Vascular Medicine, Department of Medicine, CHUV, CH 1011 Lausanne, Switzerland
    Expert Opin Drug Saf 1:45-52. 2002
    ..Meanwhile, it is crucial to emphasise that neither selective COX-2 inhibitors nor conventional NSAIDs replace aspirin in patients with a high cardiovascular risk...
  69. ncbi request reprint [Fabry disease: diagnostic due of substitutive enzyme-therapy]
    Frederic Barbey
    Division de Néphrologie CHUV, Av du Bugnon 17, 1011 Lausanne
    Rev Med Suisse Romande 122:449-53. 2002
    ..With developments in molecular biology, it is now possible to produce the human recombinant enzyme alpha-galactosidase A. More than 20 patients are now treated in Switzerland...
  70. ncbi request reprint A pregnant woman with de novo polyuria-polydipsia and elevated liver enzymes
    Frederic Barbey
    Department of Nephrology, University Hospital, Lausanne, Switzerland
    Nephrol Dial Transplant 18:2193-6. 2003
  71. ncbi request reprint [Massive hyperoxaluria]
    Frederic Barbey
    Division de Néphrologie, CHUV, Lausanne
    Rev Med Suisse Romande 124:477-82. 2004
    ..These affections represent the main etiologies of massive hyperoxaluria. If not recognized very soon and adequately treated, these conditions can progress rapidly to end stage renal failure...
  72. ncbi request reprint Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes
    Daniel Teta
    Department of Nephrology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Nephrol Dial Transplant 20:1329-35. 2005
    ..Glucose metabolism is the major factor regulating leptin. The current study was designed to test if glucose-based PD fluids might regulate leptin production in vitro...
  73. ncbi request reprint [Are the guidelines for the management of hypertensive patients followed by primary care residents and fellows?]
    A Birchmeier
    Policlinique Medicale Universitaire, Service de Néphrologie et Consultation d hypertension CHUV, 1011 Lausanne
    Rev Med Suisse 1:2081-2, 2084-6, 2088. 2005
    ..The actual recommendations are limited in their application. The control of high risk vascular patients is not better than those with a lower risk...
  74. ncbi request reprint [Population reduction of salt consumption: opportunities, impact and strategies]
    M Bochud
    Unité de prévention communautaire, Institut Universitaire de Medecine Sociale et Preventive, CHUV, 1011 Lausanne
    Rev Med Suisse 8:1443-7. 2012
    ..Regular population-based surveys will be needed to monitor the impact of current measures on salt consumption, hypertension prevalence as well as cardiovascular morbidity and mortality in the years to come...
  75. ncbi request reprint [Sleep disorders in patients with chronic renal insufficiency]
    M E Muller
    Service de Nephrologie, CHUV, Lausanne
    Rev Med Suisse 8:458-61. 2012
    ..This article discusses the prevalence and physiopathology of the most frequently encountered sleep disorders in chronic renal failure patients, and highlights the actually available therapeutic options...
  76. pmc Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country
    D Conen
    Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland
    BMC Public Health 4:9. 2004
    ....
  77. ncbi request reprint [Pregnancy in patients with underlying renal disease]
    D Golshayan
    Service de Nephrologie et Consultation d Hypertension, CHUV, 1011 Lausanne
    Rev Med Suisse 3:588, 590-2, 594-5. 2007
    ..Furthermore, if the renal disease has been diagnosed before pregnancy, a better planning of the moment of conception, as well as a tight follow-up, allow for a better maternal and obstetrical outcome...
  78. ncbi request reprint Compliance to live oral Ty21a typhoid vaccine, and its effect on viability
    C L Stubi
    University Medical Policlinic, Lausanne, Switzerland
    J Travel Med 7:133-7. 2000
    ..Electronic monitoring of compliance provides more accurate results than questionnaires. Emphasis must be put on motivating the travelers to take the vaccine as recommended...
  79. ncbi request reprint [Hypertension genetics: what have we learned so far?]
    M Pruijm
    Service de Nephrologie et Consultation d Hypertension, Institut Universitaire de Medecine Sociale et Preventive, Division de Néphrologie, CHUV, 1011 Lausanne
    Rev Med Suisse 5:1763-4, 1766-8, 1770. 2009
    ..In this article, we review some basic genetic concepts and the main research methods used to study the genetics of hypertension, as well as selected recent findings in this field...
  80. ncbi request reprint [Sodium bicarbonate to slow the progression of chronic kidney disease]
    A Rossier
    Service de Nephrologie, Departement de Medecine Interne, CHUV, Lausanne
    Rev Med Suisse 7:478-82. 2011
    ..e., halting CKD progression. These data show that sodium bicarbonate, a cheap and easily manageable treatment, may delay the progression of CKD and the need of a renal replacement therapy such as dialysis or kidney transplantation...
  81. ncbi request reprint The role of neuropeptide Y in cardiovascular regulation
    P Walker
    Division of Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Trends Pharmacol Sci 12:111-5. 1991
    ....
  82. ncbi request reprint [Antihypertensive therapy: who should be treated and to which target?]
    B Waeber
    Division de physiopathologie clinique, CHUV, 1011 Lausanne
    Rev Med Suisse 2:123-4, 126-7. 2006
    ..Antihypertensive therapy might already be required in patients exhibiting simultaneously blood pressure > or = 130/180 mmHg and diabetes and/or renal disease...
  83. doi request reprint Issues in blood pressure control and the potential role of single-pill combination therapies
    M Burnier
    Division of Nephrology and Hypertension Consultation, CHUV, Lausanne, Switzerland
    Int J Clin Pract 63:790-8. 2009
    ..Thus, the use of single-pill combination therapy for HTN should help improve BP goal attainment through improved patient compliance, leading to reduced costs for cardiovascular-related care...
  84. ncbi request reprint [Managing hypertension: the uncertainty of definitions and targets]
    V Forni
    Service de Nephrologie et Consultation d Hypertension, CHUV, 1011 Lausanne
    Rev Med Suisse 6:1709-12, 1714. 2010
    ..Besides, the debate of the "J curve", namely the possible risks associated with an excessive blood pressure reduction, is discussed...
  85. doi request reprint Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat
    Marc P Maillard
    Division of Nephrology and Hypertension, Lausanne University Hospital, Lausanne, Switzerland
    J Hypertens 27:1980-7. 2009
    ..In the present study, we investigated the in-vitro and in-vivo effects of the calcimimetic R-568 on renin release...
  86. ncbi request reprint Potassium supplementation reduces cardiac and renal hypertrophy independent of blood pressure in DOCA/salt mice
    Qing Wang
    Division of Nephrology, University Hospital, Lausanne, Switzerland
    Hypertension 46:547-54. 2005
    ..In 2-renin gene, hypertensive mice, potassium supplementation also prevents the development of cardiac hypertrophy, but the effect cannot be separated from the decrease in BP...
  87. doi request reprint Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population
    Gregoire Wuerzner
    Department of Medicine, Service of Nephrology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Am J Kidney Dis 56:303-12. 2010
    ..Obesity and African American ethnicity are established independent risk factors for the development of chronic kidney disease. No data exist about the association between obesity and renal hemodynamics in the African region...
  88. ncbi request reprint The effect of pH-neutral peritoneal dialysis fluids on adipokine secretion from cultured adipocytes
    Daniel Teta
    Department of Nephrology, Centre Hospitalier Universitaire Vaudois CHUV, Bugnon 17, 1011 Lausanne, Switzerland
    Nephrol Dial Transplant 22:862-9. 2007
    ..We have shown that low pH down-regulates leptin production. The current study was designed to test if novel pH-neutral PD fluids may regulate leptin and adiponectin secretion in vitro...
  89. doi request reprint Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain
    Gregory Aubert
    Service of Endocrinology, Diabetology and Metabolism, Department of Medicine, Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne 1011, Switzerland
    Metabolism 59:25-32. 2010
    ..These anorexigenic properties abolish both weight gain and body composition modifications in fat-fed and glitazone-treated mice. The anorexigenic properties are independent from the angiotensin II 1(A) receptor...
  90. ncbi request reprint Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs
    Marc Maillard
    Lausanne University Hospital, Service of Nephrology, Department of Internal Medicine, Rue du Bugnon 17, CHUV, 1011 Lausanne, Switzerland
    Expert Opin Drug Saf 5:83-94. 2006
    ....
  91. ncbi request reprint Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight
    Arnaud Chiolero
    Community Prevention Unit, Institute of Social and Preventive Medicine, University Hospital Center, University of Lausanne, Switzerland, Switzerland
    J Hypertens 25:2209-17. 2007
    ..We determined the prevalence of hypertension measured on up to three visits in a Swiss pediatric population and examined the association between hypertension and overweight and selected other factors...
  92. ncbi request reprint Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice
    Michel Burnier
    University of Lausanne, Service de Nephrologie et Consultation d Hypertension, Rue du Bugnon 17, CHUV, 1011 Lausanne, Switzerland
    Expert Opin Pharmacother 8:2215-23. 2007
    ..Calcium antagonists of the third generation, such as lercanidipine, have been shown to be as effective as first- and second-generation calcium antagonists, while showing a better side-effect profile...
  93. ncbi request reprint Circadian variations in blood pressure : implications for chronotherapeutics
    Christopher Hassler
    Division of Hypertension and Vascular Medicine, Department of Medicine, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    Am J Cardiovasc Drugs 5:7-15. 2005
    ..In any case, a better understanding of the importance of the circadian variations of blood pressure could certainly have a major impact on our view of the therapeutic management of hypertensive patients...
  94. doi request reprint Prevalence of microalbuminuria in the general population of Seychelles and strong association with diabetes and hypertension independent of renal markers
    Menno T Pruijm
    Department of Nephrology, University Hospital of Lausanne CHUV, Lausanne, Switzerland
    J Hypertens 26:871-7. 2008
    ..We assessed the prevalence of MAU in the general population of a middle-income country in the African region and relationships between MAU and selected cardiovascular risk factors...
  95. ncbi request reprint [Dialysis and ecology: can we do better in the future?]
    Y Vuignier
    Service de Néphrologie et Hypertension, Departement de Medecine, CHUV, 1011 Lausanne
    Rev Med Suisse 9:468-72. 2013
    ..In a world where natural resources are precious and where global warming is a major problem, it is important that not only dialysis, but all branches of medicine become more attentive to ecology...
  96. ncbi request reprint [Intermittent hemodialysis in the intensive care setting]
    S Kissling
    Service de Nephrologie et Consultation d Hypertension, CHUV, 1011 Lausanne
    Rev Med Suisse 5:445-6, 448-50. 2009
    ..The collaboration between intensive care specialists and nephrologists allows an optimized choice for a given patient and allow better move from one technic to another if required...
  97. ncbi request reprint [Chronic renal failure: what diet?]
    D Teta
    Service de Néphrologie et Hypertension, CHUV, Lausanne
    Rev Med Suisse 2:566-9. 2006
    ..This strategy, if applied, must be supported by a multidisciplinary approach involving a nephrologist and a specialised dietician. Additional dietary restrictions are not justified, except in particular situations...
  98. ncbi request reprint [Clinical and genetics aspects of Alport syndrome]
    D Golshayan
    Service de Nephrologie et Consultation d Hypertension, Departement de Medecine, CHUV, Lausanne
    Rev Med Suisse 2:593-8. 2006
    ..No specific treatment of AS is currently available. However, a better understanding of the GBM's ultrastructure, in particular of type IV collagen, will hopefully enable the identification of novel therapeutic targets...
  99. ncbi request reprint A young man with a renal colic
    F Barbey
    Department of Nephrology, University Hospital, Lausanne, Switzerland
    J Intern Med 254:605-8. 2003
    ..Finally, the observation of a delayed hypertensive response to a major renovascular insult provides incentives to discuss possible pathophysiological mechanisms involved in renovascular hypertension...
  100. ncbi request reprint Compliance in hypertension
    M Burnier
    Service de Nephrologie, Consultation d Hypertension, Lausanne, Switzerland
    EDTNA ERCA J 31:152-5. 2005
    ..This article will discuss different types of compliance, methods to measure compliance, and clinical consequences of non-compliance in hypertension...
  101. ncbi request reprint [Carbonic anhydrase inhibitors and calcium phosphate stones]
    F Barbey
    Division de Néphrologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Suisse
    Nephrologie 25:169-72. 2004
    ....